X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA member companies invested nearly $80 billion in R&D last year

By Tim McClung  |    July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.   Read More

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices

By Nick McGee  |    July 15, 2019
West Virginia, Virginia, Arizona and Illinois recently became the first states in America to adopt patient-centered legislation to bring relief and more predictability to patients facing high...   Read More

New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?

By Priscilla VanderVeer  |    July 9, 2019
For the last two years, our Let’s Talk About Cost campaign has sought to answer questions people have about their medicine costs and advance a dialogue on how we can make medicines more affordable...   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Three reasons why the latest Rx Savings Solutions analysis is misleading

By Holly Campbell  |    July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...   Read More

No matter how you structure it, government arbitration is wrong for Medicare drug coverage

By Nicole Longo  |    June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....   Read More

PhRMA responds to Florida’s request for information on drug importation

By Tiffany Haverly  |    June 26, 2019
PhRMA remains committed to working with lawmakers to ensure patients can afford and access their medicines, but importation schemes that put patient safety at risk will never be the right approach.   Read More

IP Explained: What is Section 101 and why reforms are needed

By Tom Wilbur  |    June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...   Read More

"If Washington isn’t careful, we might leave innovation behind"

By Robert Zirkelbach  |    June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates